FibroBiologics, Inc. (FBLG): Total Assets
$9.62M
As of 2025-12-31
$7.93M
As of 2026-06-30
+25.9%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.62M | -41.5% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $16.45M | +39.1% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $11.82M | +145.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $4.82M | n/a | 2024-02-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $9.62M | -41.5% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $9.70M | -4.4% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $9.71M | -27.8% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $9.51M | +4.3% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $9.49M | -82.9% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $9.31M | +26.9% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $9.98M | +4.3% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $9.24M | +3.0% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $10.06M | +78.2% |
Compare FBLG, MAIA, COCP, CANF side by side · Screen every company in Pharmaceutical Preparations ↗